Navigation Links
United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the United States Securities and Exchange Commission has declared effective its Registration Statement on Form S-4 filed with the Commission. The Registration Statement, including the joint proxy statement, is being used in connection with NeoStem's acquisition of China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP). It is anticipated that this acquisition will expand the capabilities and worldwide reach of NeoStem. China Biopharmaceutical's primary asset is a 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), located in Suzhou, China which in 2008 generated gross revenues of approximately $50 million (US) and net income of approximately $8,000,000 (US). NeoStem's 51% controlling interest in Erye will enable it to benefit from the over 100 drugs on seven GMP lines, including small molecule drugs being manufactured by Erye. Erye has been in business for more than 50 years and is respected for its quality, service and reliability. Erye has begun its three year expansion and relocation program which is anticipated to enhance revenues, profits, and manufacturing capabilities in one of the fastest growing medical markets, the Peoples Republic of China.

The acquisition is subject to customary closing conditions, including approval by the shareholders of each company at meetings of shareholders scheduled for October 29, 2009. Robin Smith, MD, CEO of NeoStem further commented, "We are excited to bring this transaction to our shareholders for a vote and, subject to their approval, begin our collaboration with Suzhou Erye Pharmaceutical Co. Ltd. as we believe it will open new markets, distrib
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army
3. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
4. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
7. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
8. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
11. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
(Date:9/1/2015)... YORK , Sept. 1, 2015 /PRNewswire-USNewswire/ ... of cancer death in American men. One ... cancer and 233,000 new cases are diagnosed annually. ... experts are using a powerful new technique, ... small and large cancer lesions, treating only the ...
(Date:9/1/2015)... ... 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine Wars ... faced with an Ebola pandemic that is on the cusp of wiping out humanity. ... world of counterterrorism, and who continues to appear in this series of books by ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... , Equine cervical facet joint problems can be caused by injuries and ... cause impingement of nerve roots or of the spinal cord itself. This can ...
Breaking Biology Technology:American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... their 2008 Annual,Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX ) ... Douglas T. Brown, Senior VP and Manager of Corporate Banking Government ... Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, ... Spherix -- Gilbert V. Levin, Ph.D., Director of Science and ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Spherix Holds Annual Shareholders Meeting 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... biosensor microchip that could significantly speed up the ... highly sensitive "nanosensors," analyze how proteins bind to ... effectiveness and possible side effects of a potential ... nanosensors can simultaneously and continuously monitor thousands of ...
... oil spill caused social disruption and psychological stress among ... the Exxon Valdez spill and the impacts are likely ... "Just ask the residents of Cordova today whether they ... Ritchie, assistant director for research of the University of ...
... study by researchers at the Virginia Institute of Marine ... does kill large numbers of copepodstiny crustaceans that are ... studyby VIMS graduate student Samantha Bickel, VIMS professor Kam ... the March issue of the Journal of Experimental ...
Cached Biology News:New biosensor microchip could speed up drug development, Stanford researchers say 2New biosensor microchip could speed up drug development, Stanford researchers say 3Gulf oil spill similar to Exxon Valdez in initial social and mental impacts, study finds 2VIMS study: Propeller turbulence may affect marine food webs 2VIMS study: Propeller turbulence may affect marine food webs 3
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Low Speed Shaker ,Product Information ... shaker is a high quality, general purpose shaker ... after the other models in the line, the ... easy-access control panel. Electronic controls are utilized for ...
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
... ActiveSight, the leading provider of X-ray ... offers fragment-based screening services to its ... involves the binding of drug-like fragments ... protein drug targets, allowing scientists to ...
Biology Products: